COClinical Orthopaedics3083-15393083-1520Bio-Byword Scientific Publishing Pty. Ltd.10.26689/co.v1i1.15927ArticleGlobal, Regional and National Burdens of Gout in People Aged 20 - 54 Years from 1990 to 2021: An Analysis Based on the 2021 Global Burden of Disease Studyhttps://artdesignp.com/journal/CO/1/1/10.26689/co.v1i1.15927LiHongqiu,WuQingzhu,LiangA,ZhaoZhonghai,JiangNan,YangFeng2026112026-08-13Objective: To describe the epidemiology of gout in people aged 20 - 54 years at global, regional, and national levels using data from the 2021 GBD study, and evaluate the impact of BMI and renal dysfunction on the burden of gout in this age group. Methods: Incidence, prevalence, and DALYs of gout were extracted from GBD 2021. Descriptive analysis was performed at global, regional, and national levels. Trends were analyzed using estimated annual percentage change (EAPC) and joinpoint regression analysis. Proportional attributable fractions of risk factors (high BMI and impaired kidney function) were calculated. Results: Globally, from 1990 to 2021, the rates of incidence, prevalence, and DALYs of gout in people aged 20 - 54 years increased. Regionally, the United States, China, and East Asia had significant increases. By SDI quintiles, the highest increases in prevalence and DALYs were in the High SDI quintile, and in incidence in the High-middle SDI quintile. Males had higher values than females. The fastest increasing periods for incidence (1996 - 2004), prevalence (1996 - 2004), and DALYs (1996 - 2003) were identified. Globally in 2021, high BMI and impaired kidney function accounted for certain proportions of DALYs, with regional and national variations. Conclusion: The burden of gout in people aged 20 - 54 years has increased significantly worldwide, with differences across various factors. Prevention strategies, improved management, and further research on gout in this age group are crucial, especially regarding its relationship with high BMI and impaired renal function.

Afinogenova Y, Danve A, Neogi T. Update on gout management: what is old and what is new. Curr Opin Rheumatol. 2022;34(2):118–124.

Murdoch R, Barry MJ, Choi HK, et al. Gout, Hyperuricaemia and Crystal Associated Disease Network (G-CAN) common language definition of gout. RMD Open 2021; 7: e001623.

Bevis M, Blagojevic-Bucknall M, Mallen C, Hider S, Roddy E.Comorbidity clusters in people with gout: an observational cohort study with linked medical record review. Rheumatology 2018; 57:1358-1363.

Cipolletta E, Tata LJ, Nakafero G, Avery AJ, Mamas MA, Abhishek A.Association between gout flare and subsequent cardiovascular events among patients with gout. JAMA 2022; 328: 440-450.

Choi HK, McCormick N, Yokose C. Excess comorbidities in gout: the causal paradigm and pleiotropic approaches to care. Nat Rev Rheumatol.2022;18(2):97–111.

Li Y, Chen Z, Xu B, Wu G, Yuan Q, Xue X, Wu Y, Huang Y, Mo S. Global, regional, and national burden of gout in elderly 1990-2021: an analysis for the global burden of disease study 2021. BMC Public Health. 2024 Nov 27;24(1):3298.

Zhang J, Jin C, Ma B, Sun H, Chen Y, Zhong Y, Han C, Liu T, Li Y. Global, regional and national burdens of gout in the young population from 1990 to 2019: a population-based study. RMD Open. 2023 Apr;9(2):e003025.

GBD 2021 Gout Collaborators. Global, regional, and national burden of gout, 1990-2020, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2024 Aug;6(8):e507-e517. doi: 10.1016/S2665-9913(24)00117-6.

Xu T, Dong W, Liu J, Yin P, Wang Z, Zhang L, Zhou M. Disease burden of Parkinson’s disease in China and its provinces from 1990 to 2021: findings from the global burden of disease study 2021. Lancet Reg Health West Pac. 2024 May 8;46: 101078.

Cao, F., Liu, Y.C., Ni, Q.Y., Chen, Y., Wan, C.H., Liu, S.Y., Tao, L.M., Jiang, Z.X., Ni,J., Pan, H.F., 2023b. Temporal trends in the prevalence of autoimmune diseases from 1990 to 2019. Autoimmun. Rev. 22, 103359.

Kim, H.J., Fay, M.P., Feuer, E.J., Midthune, D.N., 2000. Permutation tests for joinpoint regression with applications to cancer rates. Stat. Med. 19, 335–351.

Guillén AG, Te Karu L, Singh JA, Dalbeth N. Gender and ethnic inequities in gout burden and management.Rheum Dis Clin North Am 2020; 46: 693–703.

Richette P, Clerson P, Périssin L, Flipo RM, Bardin T. Revisiting comorbidi-ties in gout: a cluster analysis. Ann Rheum Dis. 2015;74(1):142–147.

Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397(10287):1843–55.

Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the national health and nutrition examination survey, 2007–2016.Arthritis Rheumatol. 2019;71(6):991–999.

Ashiq K, Bajwa MA, Tanveer S, Qayyum M, Ashiq S, Khokhar R, Abid F. A comprehensive review on gout: The epidemiological trends, pathophysiology, clinical presentation, diagnosis and treatment. J Pak Med Assoc. 2021 Apr;71(4):1234-1238.

Carcione J, Bodofsky S, LaMoreaux B, Schlesinger N. Beyond Medical Treatment: Surgical Treatment of Gout. Curr Rheumatol Rep. 2020 Nov 24;23(1):1

Moi JH, Sriranganathan MK, Falzon L, Edwards CJ, van der Heijde DM, Buchbinder R. Lifestyle interventions for the treatment of gout: a summary of 2 Cochrane systematic reviews. J Rheumatol Suppl. 2014 Sep;92:26-32.

Hoon E, Edwards J, Robinson P, Rowett D, Stocks N, Keen HI, Hill CL. How is gout currently managed, and is there interest in changing the way we deliver care? A qualitative exploratory study. Aust J Gen Pract. 2024 Nov;53(11):864-871.

Deng F, Wang Q, Wen X, Xu X, Jia L, He H, Wang X, Xie Y, Li H, Qiao L, Han J. Association between Body Mass Index and Serum Uric Acid: mediation analysis involving liver enzymes indicators. BMC Public Health. 2024 Oct 30;24(1):3007.

Cao M, Ahmad Yusof H, Chen J, Zhou L. Development and validation of a knowledge, attitude, and practice questionnaire regarding exercise and exergames for obese patients with gout. BMC Public Health. 2024 Sep 27;24(1):2638.